JUN and breast carcinoma: Knockdown of Jun expression in luminal cells increased resistance to entinostat (Fig. 4c, d), and genomic loss of Jun at 1p32, which was found in 17–23% of patients with luminal breast cancer, was significantly prognostic among patients with luminal breast cancer who received anti-hormonal therapies (Fig. 6).